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Permanent pacemakers capable of triggered ventricular 
stimulation were implanted in 28 patients with a history 
of sustained ventricular tachycardia or fibrillation. Non-
invasive programmed ventricular stimulation was per-
formed on 125 occasions during follow-up periods rang-
ing from 1 to 25 months and was used to assess the 
efficacy of antiarrhythmic drug therapy, drug or dosage 
changes and left ventricular endocardial resection. Drug 
or dosage changes based on noninvasive programmed 
Programmed ventricular stimulation is a useful technique 
for the selection of effective long-term drug therapy for 
recurrent sustained ventricular tachycardia (1-4). Unfor-
tunately, it is time-consuming, expensive and uncomfortable 
for the patient (5). In addition, in one large study (6), com-
plications related to the placement or maintenance of tem-
porary electrodes occurred in 5.6% of patient studies. Most 
candidates for serial electrophysiologic study for selection 
of antiarrhythmic drug therapy have proved refractory to 
empiric therapy with standard agents and require prolonged 
testing and, often, investigational drugs. During antiar-
rhythmic drug testing and therapy with partially effective 
agents, spontaneous sustained ventricular tachycardia may 
occur. It can often be terminated with bursts of ventricular 
pacing using either a temporary electrode or a permanent 
pacemaker (7-10). Use of an externally controllable, im-
planted pacemaker makes it possible to perform serial testing 
of drug efficacy after initial hospital discharge without the 
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ventricular stimulation were made in 19 of the 28 pa-
tients. In addition, 126 episodes of spontaneous sustained 
ventricular tachycardia were terminated noninvasively 
in nine patients. It is concluded that a permanent pace-
maker capable of triggered ventricular stimulation is 
useful in patients with ventricular tachycardia or fibril-
lation that is difficult to control. 
(J Am Coli CardioI1985;6:206-12) 
cost or risk of reinstrumentation, and makes immediately 
available a device that can terminate spontaneous sustained 
ventricular tachycardia, and provide backup ventricular de-
mand pacing. We report on the results of the use of three 
such pacemakers in patients with recurrent sustained ven-
tricular tachycardia. 
Methods 
Clinical characteristics of study patients (Table 1). After 
giving informed written consent, 28 patients, aged 29 to 73 
years (mean 57.8), underwent implantation of a permanent 
ventricular pacemaker capable of triggered ventricular stim-
ulation. The protocol followed that approved by the Baylor 
College of Medicine Institutional Review Board on Novem-
ber 10, 1981. Eighteen patients had recurrent sustained ven-
tricular tachycardia and 10 had ventricular tachycardia com-
plicated by ventricular fibrillation. Twenty-six patients had 
atherosclerotic coronary artery disease complicated by myo-
cardial infarction, one patient had a benign infiltrating car-
diac lipoma and one patient had idiopathic cardiomyopathy 
with normal coronary arteries. Left ventricular ejection frac-
tion ranged from 9 to 68% (mean 31). Before referral for 
electrophysiologic study. the patients had received empir-
ically as many as six (mean 2.9) standard or investigational 
antiarrhythmic agents without achieving control of their 
arrhythmia. 
Electrophysiologic study. Systematic electrophysio-
logic study was performed in 27 patients in the drug-free 
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Table 1. Patient Characteristics 
Age (yr) 
at Implantation 
Case & Sex 
Ejection 
Cardiac Fraction 
Disease (%) 
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Clinical PVS Before 
Drug Implantation 
Arrhythmias Failures (days/drugs) Device Used 
Group I (pacemaker implanted at conclusion of electrophysiologic study) 
I 29F Tumor 61 VT 5 III Spectrax 
2 53M CAD 10 VTNF 2 10/4 Omni-Orthocor 
3 58M CAD 9 VTNF 2 4/3 RF 
4 60M CAD 42 VT 2 4/3 Omni-Orthocor 
5 46M CAD 25 VT 2 3/3 Omni-Orthocor 
6 57M CAD 68 VTNF 2 5/5 Omni-Orthocor 
7 49M CAD 22 VT 3 2/1 Omni-Orthocor 
8 52M CAD 27 VT 3 2/1 Omni-Orthocor 
9 64M CAD 21 VTNF 4 4/4 Omni-Orthocor 
10 60M CAD 17 VT 4 3/2 Omni-Orthocor 
II 73M CAD 24 VT I 5/3 Omni-Orthocor 
12 59M CAD 45 VTNF 2 1/1 RF 
13 57M CAD 30 VT 4 3/3 Omni-Orthocor 
14 59M CM 36 VTNF 4 4/4 Omni-Orthocor 
15 63M CAD 17 VTNF 4 3/3 Omni-Orthocor 
16 48M CAD 29 VTNF 4 0/0 Omni-Orthocor 
17 59M CAD 20 VTNF 0 3/3 Omni-Orthocor 
18 59M CAD 17 VT 2 3/3 Omni-Orthocor 
19 45M CAD 37 VT 2/2 RF 
20 63M CAD 23 VT 5 III Omni-Orlhocor 
21 57M CAD 22 VT 3 III RF 
22 64M CAD 44 VT 2 2/2 Spectrax 
Group II (pacemaker implanted at time of endocardial resection) 
23 62M CAD 49 VTNF 4 7/4 RF 
24 62M CAD 33 VT 2 4/5 RF 
25 66M CAD 42 VT 4 3/2 RF 
26 62M CAD 32 VT 6 110 RF 
27 67M CAD 22 VT 2 211 RF 
28 65M CAD 45 VTNF 3 3/3 RF 
CAD = coronary artery disease; CM = cardiomyopathy; F = female; M = male; PVS = programmed ventricular stimulation; RF = radiofrequency; 
VF = ventricular fibrillation; VT = ventricular tachycardia. 
post absorptive state with use of two or three percutaneously 
placed quadripolar electrodes. One patient had incessant 
ventricular tachycardia and was not studied before initiation 
of antiarrhythmic therapy. Ventricular tachycardia was in-
ducible in all patients studied. The patients underwent I to 
10 (mean 3.1) serial studies with temporary electrodes and 
testing of 1 to 5 standard or investigational agents (Table 
1). When it became apparent that long-term serial electro-
physiologic testing might be useful or when a temporary 
electrode could no longer be maintained, implantation of a 
permanent pacemaker capable of triggered ventricular stim-
ulation was recommended. 
Patient groups. A permanent pacemaker was implanted 
in 22 patients (Group I) to continue serial electrophysiologic 
study and monitor antiarrhythmic drug therapy after hospital 
discharge. A pacing device in the remaining six patients 
(Group II) was implanted at the time of mapping-directed 
left ventricular endocardial resection for ventricular 
tachycardia. 
Pacing devices. The Cordis Omni-Orthocor model 234-
A unipolar pulse generator was implanted in 16 patients in 
Group I. With the application of a magnet, the pacemaker 
is converted from inhibited to triggered mode with a re-
fractory period of 175 ms. The pulse generatot can then be 
activated by skin stimulation using either a hand-held cus-
tom device, a programmable stimulator or any conventional 
external pacemaker (Fig. I). 
The Medtronic model 5998-R bipolar radio frequency re-
ceiver was implanted in 10 patients (4 in Group I and 6 in 
Group II). A hand-held custom digital radiofrequency 
transmitter (model 5998 TDA) induces power in the im-
planted coil to deliver a burst of ventricular pacing. A mod-
ification of this device allows the transmitter to be coupled 
to any programmable stimulator (11). 
The Medtronic model 5985 unipolar pulse generator was 
implanted in two patients in Group I. A "temporary" pro-
gram converts this device from inhibited to triggered mode, 
allowing burst pacing and programmed ventricular stimu-
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lation with a pacemaker refractory period of 220 ms. A 
custom-designed programmer (model 9701-2347S) allows 
shortening of the pacemaker refractory periods to 150 ms. 
Pacing leads. In Group I, a unipolar transvenous lead 
was used in 16 patients who received a Cordis Omni-Or-
thocor model 234-A or Medtronic Spectrax model 5985 
pulse generator. A single epicardial screw-in lead was used 
in two patients, one with a model 234-A pulse generator 
and one with a Medtronic model 5985 pulse generator. A 
bipolar trans venous lead was used in four patients who re-
ceived a Medtronic model 5998-R radiofrequency receiver. 
In Group /I, two epicardial leads were used in all six patients. 
Study technique. Patients were studied in the nonse-
dated, postabsorptive state in the coronary care unit, non-
invasive laboratory or electrophysiology laboratory. An in-
travenous line was inserted and a defibrillator and standard 
resuscitation equipment were available. Programmed stim-
ulation was performed using either a Medtronic model 5325 
programmable stimulator or a digital programmable stim-
ulator (model DTU-I01C, Bloom Associates). 
Serial electro physiologic studies were performed using 
standard ventricular extrastimulation techniques, including 
the introduction of single extrastimuli during sinus rhythm 
and at a ventricular drive cycle length of 600 and 500 ms, 
and up to four extrastimuli at a drive cycle length of 500 
ms. Burst ventricular stimulation was then performed with 
decremental decreases in cycle length to 200 ms or to that 
resulting in 2: 1 noncapture of the ventricles. 
Recordings in the electrophysiology laboratory were made 
on an Electronics for Medicine VR -16 oscilloscopic recorder 
at a paper speed of 100 mm/s, and in the coronary care unit 
and noninvasive laboratory on a Marquette MAC-l com-
puter-assisted electrocardiograph at a paper speed of 50 
mm/s. Studies were performed on inpatients as indicated 
during initial drug testing or after drug failure and on out-
patients at intervals of 1 or 3 months. 
Results 
Follow-up. Group I. The 22 patients in Group I have 
been followed up for 184 patient-months (range 1 to 25, 
mean ± SD 8.4 ± 6.6 months per patient). One patient 
(Case 2) had sudden cardiac death. Two patients (Cases 3 
and 13) died after left ventricular endocardial resection after 
failure of antiarrhythmic therapy. One patient (Case 11) died 
of amiodarone-induced pulmonary fibrosis. The implanted 
pacemaker was removed from one patient (Case 7) because 
of infection of the epicardial electrode system and pocket. 
The 17 remaining patients are alive, are on antiarrhythmic 
therapy and continue to be followed up by serial noninvasive 
electrophysiologic study. 
Group II. The six patients in Group II have been fol-
lowed up for 73 patient-months (range 3 to 19, mean ± 
SD 12.2 ± 6.1 months per patient). There have been no 
deaths and only one patient (Case 26) remains on antiar-
rhythmic therapy. 
JACC Vol. 6, No. I 
July 1985:206--12 
Serial electrophysiologic studies. Group I. The 22 pa-
tients in this group underwent a total of 110 serial electro-
physiologic studies (range 1 to 13, mean 5.0 ± 3.0 studies 
per patient) for drug and dosage selection (Table 2). During 
these studies, sustained ventricular tachycardia was induced 
259 times and terminated 239 times by pacing and 20 times 
by cardioversion. No adverse effects on pacemaker func-
tion, R wave amplitude or thresholds were noted after car-
dioversion. The efficacy of one to five antiarrhythmic drugs 
was tested in each patient. The drugs tested included lido-
caine, procainamide, quinidine, disopyramide, proprano-
lol, pindolol, phenytoin, ethmozine, lorcainide and amio-
darone. Up to seven drug or dosage changes were made in 
each patient on the basis of information obtained during 
serial electrophysiologic study. Eighteen patients ultimately 
received amiodarone as a part of their antiarrhythmic treat-
ment. In these patients, drug efficacy was determined by 
ambulatory monitoring, exercise testing, inducibility of ven-
tricular tachycardia and cycle length of induced ventricular 
tachycardia. The other seven patients were reevaluated by 
programmed stimulation because it was necessary to change 
the drug or dosage. After initial hospital discharge, six pa-
tients developed intolerable side effects from the antiar-
rhythmic drug (amiodarone in four, pindolol in one and 
lorcainide in one) and underwent additional testing to iden-
tify tolerable, efficacious dosages or other drugs. 
Group II. The six patients in this group underwent a 
total of 15 serial noninvasive electrophysiologic studies after 
endocardial resection. Three patients (Cases 24, 27 and 28) 
had no inducible or spontaneous ventricular tachycardia 
postoperatively. In two patients ventricular tachycardia was 
inducible postoperatively. In one (Case 23) spontaneous 
ventricular tachycardia has not occurred; in the other (Case 
25) it developed after treatment with amiodarone. This 
patient has had no ventricular tachycardia for more than 1 
year without antiarrhythmic therapy. In one patient (Case 
26), ventricular tachycardia recurred 3 months after endo-
cardial resection. He then underwent serial drug testing and 
follow-up according to the protocol for the patients in Group 
I. 
Spontaneous sustained ventricular tachycardia. Group 
I. Nine of the 22 patients (Cases 2,3,7,9,11,13,15, 
16 and 20) developed spontaneous sustained ventricular 
tachycardia or fibrillation after implantation of a permanent 
pacemaker. During the initial hospitalization, one patient 
(Case 13) had exercise-induced ventricular tachycardia that 
could not be terminated by pacing. Spontaneous recurrences 
of sustained or non sustained tachycardia were seen after 
initial hospital discharge in eight patients. All eight had 
inducible ventricular tachycardia at the serial electrophys-
iologic study immediately before the spontaneous event. 
One of these patients (Case 2) had sudden cardiac death 4 
weeks after a change from inducible slow (140/min), stable 
ventricular tachycardia to inducible fast (200/min), unstable 
ventricular tachycardia. Each of the other seven patients had 
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Table 2. Results of Triggered Ventricular Stimulation and Follow-Up 
Induced VT Spontaneous VT 
Case 
TVS 
Sessions 
Sustained 
VT 
Method of 
Tennination 
Pacing CDVN 
No. of 
Drugs 
Tested 
No. of 
Drug 
or Dosage 
Changes 
Sustained 
VT 
Method of 
Tennination 
Pacing CDVN 
Duration of 
Follow-up 
(mo) Status 
Group I (pacemaker implanted at conclusion of electrophysiologic study) 
I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
I 
7 
4 
6 
5 
7 
7 
13 
7 
4 
3 
5 
5 
8 
2 
3 
5 
3 
10 
I 
3 
o 
19 
4 
7 
3 
o 
20 
14 
4 
8 
o 
19 
5 
9 
3 
3 
7 
I 
105 
I 
o 
o 
17 
3 
7 
2 
o 
20 
14 
o 
4 
8 
o 
17 
3 
6 
2 
o 
7 
o 
105 
1 
o 
o 
2 
1 
o 
o 
o 
o 
o 
o 
o 
2 
2 
3 
3 
o 
1 
o 
o 
o 
2 
3 
3 
1 
2 
5 
2 
2 
o 
1 
o 
3 
3 
3 
4 
7 
o 
1 
o 
3 
6 
2 
o 
2 
2 
3 
1 
2 
o 
o 
o 
o 
o 
33 
o 
6 
o 
7 
o 
10 
32 
o 
o 
o 
3 
o 
o 
o 
o 
o 
o 
o 
o 
o 
32 
o 
6 
o 
5 
o 
10 
32 
o 
o 
o 
2 
o 
o 
o 
o 
1 
o 
o 
o 
o 
o 
1 
o 
o 
o 
3 
o 
o 
o 
o 
o 
o 
o 
o 
25 
18 
18 
18 
6 
16 
10 
IO 
9 
8 
6 
7 
6 
5 
5 
4 
4 
3 
2 
2 
A 
D 
D 
A 
A 
A 
E 
A 
A 
A 
D 
A 
D 
A 
A 
A 
A 
A 
A 
A 
A 
A 
Group II (pacemaker implanted at time of endocardial resection) 
23 
24 
25 
26 
27 
28 
1 
5 
6 
1 
o 
6 
19 
o 
o 
o 
o 
6 
17 
o 
o 
1 
o 
o 
2 
o 
o 
o 
o 
2 
2 
o 
o 
o 
o 
4 
4 
o 
o 
o 
o 
2 
37 
o 
o 
o 
o 
2 
36 
o 
o 
o 
o 
o 
1 
o 
o 
19 
16 
16 
12 
7 
3 
A 
A 
A 
A 
A 
A 
A = alive; CDVN = cardioversion; D = dead; E = explanted; TVS = triggered ventricular stimulation; VT = ventricular tachycardia. 
I to 32 episodes of spontaneous ventricular tachycardia ter-
minated by pacing and were reevaluated by programmed 
stimulation because it was necessary to change the drug or 
dosage. In Group I, 89 of the 94 spontaneously occurring 
episodes of sustained ventricular tachycardia were termi-
nated by pacing. 
Group II. Two of the six patients (Cases 25 and 26) had 
39 episodes of spontaneous ventricular tachycardia; 38 of 
these episodes were terminated by ventricular burst pacing. 
One episode required cardioversion because the radiofre-
quency transmitter was not available. 
Discussion 
Role of permanent pacemaker in serial programmed 
ventricular stimulation. Since the first description (12) of 
the induction of ventricular tachycardia, programmed stim-
ulation of the ventricle has evolved into a widely applied 
and clinically useful technique for evaluation of drug therapy 
for ventricular tachycardia. This technique reliably repro-
duces spontaneously occurring ventricular tachycardia in the 
laboratory and rarely produces sustained ventricular tachy-
cardia in patients without spontaneous ventricular tachy-
cardia (13,14). It appears to be useful in patients with ven-
tricular fibrillation as well as ventricular tachycardia 
(l ,2,4, 15, 16). As greater use has been made of the tech-
nique, several limitations have become apparent. The stud-
ies are time-consuming and require a sophisticated labora-
tory and the commitment of a medical team (5). Although 
permanent pacemaker implantation is expensive, the im-
plantation of a device capable of triggered ventricular stim-
ulation obviates the need for maintenance of a temporary 
electrode for long-term study, placement of temporary elec-
trodes for subsequent study and hospitalization for long-
term follow-up studies. Staff requirements for studies per-
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fonned using a pennanently implanted device are less be-
cause, in our experience, the studies can be safely perfonned 
by two physicians and a nurse or physician's assistant. The 
studies are much shorter in duration because no time is spent 
placing electrodes, and they are better tolerated by the pa-
tient. They can also be perfonned wherever a three-channel 
electrocardiograph and resuscitation equipment are available. 
DiMarco et al. (6) reported complications not due to 
arrhythmia in 20 of 359 patients undergoing electrophysi-
ologic study. Some of the many complications, such as 
infection, pneumothorax and pulmonary embolization, that 
occurred during placement or maintenance of electrodes for 
serial drug testing might have been avoided by implantation 
of a pennanent pacemaker. 
Patient management. Mason and Winkle (2) reported 
in 1980 that 80% of patients receiving a drug predicted to 
be effective by electrophysiologic study had no recurrence 
of ventricular tachycardia at 6 months' follow-up. By 18 
months, however, 32% of patients had recurrent ventricular 
tachycardia and were, therefore, potential candidates for 
further electrophysiologic study. Complete electrophysio-
logic study would not be necessary at this stage and all data 
could be obtained by ventricular stimulation using an im-
planted pacemaker and surface electrocardiographic record-
ings. As the duration of follow-up of patients treated on the 
basis of electrophysiologic study increases, one might ex-
pect the evolution of the disease processes to change the 
nature of the arrhythmia and the drug responsiveness of the 
tachycardia. Drug changes can also be made without in-
strumentation in patients who develop intolerable side ef-
fects to effective or partially effective drugs. 
The use of burst pacing with both temporary and per-
manent pacing systems for the termination of supraventric-
ular and ventricular tachycardias is well documented. In 
1967, Haft et al. (17) first described the effectiveness of 
rapid atrial pacing for the tennination of atrial flutter. In 
1971, Bennett and Pentecost (9) reported the successful 
tennination of ventricular tachycardia with overdrive pacing 
using a temporary electrode. Patient-activated radiofre-
quency pacing for supraventricular tachycardia was first de-
scribed in 1974 by Williams and Davison (18). Later reports 
by others (19-22) confinned the effectiveness of the tech-
JACC Vol. 6. No. I 
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nique. Automatic pacemakers for the tennination of supra-
ventricular tachycardia have been described (23,24). 
Griffin et al. (25) reported the use of a pennanentIy 
implanted, automatic pacemaker for the tennination of ven-
tricular tachycardia in 1981. Fisher et al. (10), in 1982, 
further described the use of automatic or patient-activated 
devices for tennination of ventricular tachycardia in 13 pa-
tients. However, the use of pennanent pacing for the ter-
mination of ventricular arrhythmias has been limited by the 
risk of pacing-induced acceleration or induction of ventric-
ular fibrillation (26). Although automatic or patient-acti-
vated devices should only rarely be considered in patients 
with ventricular tachycardia, physician-activated devices may 
be safely used in patients with stable ventricular tachycardia 
wherever equipment for cardioversion is available. 
The increasing use of amiodarone has changed the ap-
proach to ventricular tachycardia in many patients. The 
usefulness of electrophysiologic study has been questioned 
in these patients because ventricular tachycardia often re-
mains inducible despite a good clinical response to the drug 
(27-29). Recent reports (30,31), however, suggest that cer-
tain aspects of programmed ventricular stimulation are use-
ful in predicting the clinical response to amiodarone. The 
time required to demonstrate a response to amiodarone by 
either continuous monitoring or programmed stimulation 
ranges from 1 to 4 weeks (28). Because many of the side 
effects of amiodarone therapy are partly dose-related (28,32), 
it is important to identify beneficial effects as early as pos-
sible so that the dose can be decreased. The implantation 
Figure 1. Simultaneous surface electrocardiographic leads I, II, 
III and V I are shown during initiation and termination of ventricular 
tachycardia utilizing the Omni-Orthocor pacemaker. During sinus 
rhythm (beats I and 2) VVT sensing is seen with the magnet in 
place. First, second and third programmed ventricular stimuli (S2' 
S3, S4, respectively) denote ventricular pacing spikes triggered 
from skin stimuli delivered by an external programmable stimu-
lator. VT indicates the first four beats of induced ventricular tachy-
cardia, sensed in VVT mode. Burst indicates a train of eight paced 
beats in response to external skin stimulation, at a cycle length 
(CL) of 410 ms. Two escape paced beats follow termination of 
ventricular tachycardia, and sinus rhythm ensues (last two 
complexes). 
I 
82 S3 S4 I-- VT ---t Bursl " "" 1'", n,t 
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of a pacemaker capable of programmed ventricular stimu-
lation early in the course of amiodarone therapy permits 
frequent retesting without the risk, expense and physical 
discomfort of maintaining or replacing a temporary elec-
trode. Frequent retesting may allow earlier decreases in 
amiodarone dosage. Because amiodarone increases the cycle 
length of spontaneous and induced ventricular tachycardia 
(28), the arrhythmia is better tolerated by the patient and 
may be more easily terminated by pacing. If the rate of 
ventricular tachycardia is slowed by amiodarone, the patient 
will usually remain conscious and be able to travel to an 
emergency room where the tachycardia can be safely ter-
minated using the implanted device. 
Implanted pacing devices. Each of the devices used in 
our study has significant limitations. The Medtronic Spec-
trax model 5985 pulse generator requires a custom-designed 
programmer to achieve short refractory periods. An ad-
justable, hand-held programmer for burst pacing alone (model 
2331) is available on an investigational basis and may be 
supplied to patients with a Spectrax pulse generator. The 
hand-held custom transmitter supplied for use with the Med-
tronic model 5998-R radiofrequency receiver permits easy 
adjustment of the burst pacing rate and is well suited for 
use by physicians. However, the device does not provide 
for demand pacing, which is sometimes required for un-
derlying or drug-induced sinus node dysfunction or atrio-
ventricular block, and it cannot be activated by skin stim-
ulation. The hand-held custom device (Orthodriver III) cur-
rently supplied to us with the Cordis Omni-Orthocor model 
234A requires a custom programmer to adjust the burst 
pacing rate. Therefore, patients with ventricular tachycardia 
of varying cycle lengths must either go to a center where 
programming is available or be supplied with a device pro-
grammed to a cycle length capable of terminating all cycle 
lengths of ventricular tachycardia. 
On the basis of our experience, the ideal pulse generator 
for patients such as those described would be multipro-
grammable, capable of backup demand pacing and easily 
converted to triggered ventricular pacing with a shortened 
refractory period using nonproprietary equipment such as a 
magnet. It should be activated by skin stimulation either 
through a programmable stimulator or pacemaker or by a 
hand-held device that can be adjusted without a programmer. 
Clinical implications. Patients were entered into our 
study on the basis of the failure of empiric therapy, repro-
ducible induction of ventricular tachycardia and the belief 
that serial electrophysiologic study would be useful on a 
long-term basis. Certain characteristics have been identified 
in those patients in whom the pacing device has been most 
useful. Patients whose ventricular tachycardia remained in-
ducible at the conclusion of initial serial electrophysiologic 
testing regardless of the antiarrhythmic drug ultimately se-
lected were more likely to have subsequent drug or dosage 
changes based on noninvasive serial electrophysiology study. 
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Serial noninvasive electrophysiologic study was useful in 
patients whose arrhythmia was unchanged by therapy as 
judged by ambulatory electrocardiographic monitoring. After 
the development of side effects from antiarrhythmic therapy 
or recurrence of ventricular tachycardia during therapy, se-
rial noninvasive electrophysiologic study provided a safe 
and well-tolerated method for optimizing treatment. Al-
though implantation of a permanent pacemaker at the time 
of left ventricular endocardial resection entails little added 
risk or expense to the patient, the device appears to be 
therapeutically useful only in patients whose tachycardia 
recurs postoperatively. 
Thus, permanent pacemakers capable of serial nonin-
vasive electrophysiologic study by triggered ventricular 
stimulation appear to be useful in patients who have ven-
tricular tachycardia that remains inducible during drug ther-
apy, whose arrhythmia remains unchanged as assessed by 
ambulatory electrocardiographic monitoring or who have 
side effects or recurrence of ventricular tachycardia after 
initial hospital discharge. 
We acknowledge the expertise of Kalene Farley in the preparation of the 
manuscript. 
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